We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Inoveon for Various cGMP Violations
FDA Warns Inoveon for Various cGMP Violations
June 2, 2005
The FDA recently issued a warning letter to devicemaker Inoveon, claiming the facilities or controls used for — or the methods used in — manufacturing the company’s Diabetic Retinopathy 3DT System violate cGMP requirements.